The Journal of Infectious Diseases最新文献

{"title":"From Bite to Brain: Arboviral Neuropathogenesis","authors":"Anne Piantadosi, Alyssa B Evans","doi":"10.1093/infdis/jiaf182","DOIUrl":"https://doi.org/10.1093/infdis/jiaf182","url":null,"abstract":"Neuropathogenic arboviruses cause a substantial burden of human disease throughout the world. However, diagnosing and treating arboviral neurological disease remains difficult, largely due to the similar clinical presentation of many neuropathogenic arboviruses, a lack of quick and specific diagnostic assays for many viruses, and limited knowledge about the molecular pathogenesis of these viruses. These limitations pose great challenges to the treatment of neuropathogenic arboviral disease. This is likely to become an even greater problem as the arthropod vectors for these viruses expand into new geographic regions due to climate change, possibly leading to new and larger outbreaks. This review summarizes the current knowledge of the mechanisms of pathogenesis for the genetically diverse neuropathogenic arboviruses endemic to the U.S., as well as their epidemiology, clinical presentations, and outcomes.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"99 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B–Associated Hospitalizations—United States, September 1, 2023–May 31, 2024","authors":"Nathaniel M Lewis, Elizabeth J Harker, Seana Cleary, Yuwei Zhu, Carlos G Grijalva, James D Chappell, Jillian P Rhoads, Adrienne Baughman, Jonathan D Casey, Paul W Blair, Ian D Jones, Cassandra A Johnson, Natasha B Halasa, Adam S Lauring, Emily T Martin, Manju Gaglani, Shekhar Ghamande, Cristie Columbus, Jay S Steingrub, Abhijit Duggal, Jamie R Felzer, Matthew E Prekker, Ithan D Peltan, Samuel M Brown, David N Hager, Michelle N Gong, Amira Mohamed, Matthew C Exline, Akram Khan, Samantha A N Ferguson, Jarrod Mosier, Nida Qadir, Steven Y Chang, Adit A Ginde, Anne Zepeski, Christopher Mallow, Estelle S Harris, Nicholas J Johnson, Kevin W Gibbs, Jennie H Kwon, Ivana A Vaughn, Mayur Ramesh, Basmah Safdar, Diya Surie, Fatimah S Dawood, Sascha Ellington, Wesley H Self","doi":"10.1093/infdis/jiaf185","DOIUrl":"https://doi.org/10.1093/infdis/jiaf185","url":null,"abstract":"Background The 2023–2024 influenza season included sustained elevated activity from December 2023–February 2024 and continued activity through May 2024. Influenza A(H1N1), A(H3N2), and B viruses circulated during the season. Methods During September 1, 2023–May 31, 2024, a multistate sentinel surveillance network of 24 medical centers in 20 U.S. states enrolled adults aged ≥18 years hospitalized with acute respiratory illness (ARI). Consistent with a test-negative design, cases tested positive for influenza viruses by molecular or antigen test, and controls tested negative for influenza viruses and SARS-CoV-2. Vaccine effectiveness (VE) against influenza–associated hospitalization was calculated as (1 − adjusted odds ratio for vaccination) × 100%. Results Among 7690 patients, including 1170 influenza cases (33% vaccinated) and 6520 controls, VE was 40% (95% CI: 31%–48%) with varying estimates by age (18–49 years: 53% [34%–67%]; 50–64 years: 47% [31%–60%]; ≥65 years: 31% [16%–43%]). Protection was similar among immunocompetent patients (40% [30%–49%]) and immunocompromised patients (32% [7–50%]). VE was statistically significant against influenza B (67% [35%–84%]) and A(H1N1) (36% [21%–48%]) and crossed the null against A(H3N2) (19% [-8%–39%]). VE was higher for patients 14–60 days from vaccination (54% [40%–65%]) than >120 days (18% [-1%–33%]). Conclusions During 2023–2024, influenza vaccination reduced the risk of influenza A(H1N1)– and influenza B–associated hospitalizations among adults; effectiveness was lower in patients vaccinated >120 days prior to illness onset compared with those vaccinated 14–60 days prior.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"183 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of pre-existing coronavirus antibodies on SARS-CoV-2 infection outcomes in exposed household members","authors":"Ilse Westerhof, Reina Sikkema, Ganna Rozhnova, Janko van Beek, Marion Koopmans, Patricia Bruijning-Verhagen","doi":"10.1093/infdis/jiaf172","DOIUrl":"https://doi.org/10.1093/infdis/jiaf172","url":null,"abstract":"Background/Rationale We investigated the effect of pre-existing antibodies against SARS-CoV-2 and seasonal human coronaviruses on infection outcomes in Omicron BA1/2 exposed household members from January to March 2022. Methods Data from a prospective household study in the Netherlands were used including 63 households with 195 household members exposed to a SARS-CoV-2 Omicron BA1/2 index case. The protocol included repeated nose-throat swab and saliva RT-PCR testing, paired serology, and self-reported daily symptom scoring by household members. Infection outcomes included the occurrence of secondary infections, symptom burden, and CT-value trajectories. We studied the effect of baseline binding antibody levels for SARS-CoVs and seasonal coronaviruses (hCoV) NL63, 229E, HKU1 and OC43 spike protein, on SARS-CoV-2 infection outcomes. Results 132 of 195 (68%) exposed household members developed a SARS-CoV-2 infection. Among exposed household members, higher levels of SARS-CoV-2 at baseline were associated with a reduced risk of secondary infection (adjusted Odds ratio 0.73; 95% Confidence interval 0.55-0.99). No significant differences between antibody levels and symptom burden or CT-value trajectories were observed. Conclusions Our study suggests that prior SARS-CoV-2 antibodies provide some protection against Omicron BA.1/BA.2 infection, while effects on symptom burden or CT-value could not be demonstrated. The results highlight the relatively limited, but not negligible role of cross-protective antibodies, especially when facing immune escape variants of SARS-CoV-2.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measles seroprevalence in infants under nine months of age in low- and middle-income countries: a systematic review and meta-analysis","authors":"Darren Suryawijaya Ong, Claire von Mollendorf, Kim Mulholland, Lien Anh Ha Do","doi":"10.1093/infdis/jiaf177","DOIUrl":"https://doi.org/10.1093/infdis/jiaf177","url":null,"abstract":"Background Measles infections cause significant morbidity and mortality in low- and middle-income countries (LMICs), especially infants under nine months. Measles seroprevalence data in infants too young to be vaccinated can identify immunity gaps to inform immunisation strategies. Our systematic review and meta-analysis describes measles seroprevalence in infants <9 months in LMICs. Methods We systematically searched journal articles and conference abstracts from 1 January 2018 to 25 December 2024 across 10 databases and registers (PROSPERO: CRD42023429586). We included observational studies presenting measles antibody seroprevalence data from infants <9 months in LMICs. Studies underwent dual reviewer screening and risk of bias was assessed using an adapted Joanna Briggs Institute tool. Seropositivity estimates were pooled using a random-effects inverse variance model. We performed subgroup analyses by country income level, measles vaccine coverage and measles incidence. Results Among 1421 studies identified, 34 were included. Most studies were from middle-income countries (n=30/34) using hospital/health-centre data (n=22/34). Risk of bias was generally low or moderate (n=33/34). The meta-analysis included 20 studies (N=8230 infants) with high inter-study heterogeneity. Pooled seropositivity was highest at birth (81%, 95% CI: 75-88), decreasing to 30% (95% CI: 24-35) by four months, and lowest at seven months (18%, 95% CI: 0-41). Subgroup analyses showed minimal differences between categories. Conclusions Seventy percent of infants are seronegative by four months old and unprotected from measles before their first vaccine dose at 9-12 months. Early administration of measles-containing vaccines could provide sustained protection throughout infancy.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Dengue Virus Antibody Avidity Correlates with Protection Against Symptomatic Dengue Virus Infection","authors":"Isamu Tsuji, David Dominguez, Jonathan Hernandez, Eloi Kpamegan, José Victor Zambrana, Angel Balmaseda, Hansi Dean, Mayuri Sharma, Eva Harris","doi":"10.1093/infdis/jiaf171","DOIUrl":"https://doi.org/10.1093/infdis/jiaf171","url":null,"abstract":"Antibody avidity is indicative of antibody affinity maturation following virus infection or vaccination. To determine correlation between preexisting anti-dengue virus (DENV) antibody avidity and secondary DENV exposure outcomes, we assessed anti-DENV antibody avidity, represented as avidity index (antibody response/dissociation rate) in sera of Nicaraguan Pediatric Dengue Cohort Study participants prior to symptomatic or inapparent secondary DENV infections. The avidity index was significantly higher in participants who subsequently developed inapparent versus symptomatic infections. Risk factor analysis suggested that odds of inapparent DENV infection increase as avidity index increases. Antibody avidity index is an important parameter for characterizing protective DENV immune responses.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness, safety, and pharmacokinetics of linezolid in pediatric bacterial central nervous system infections","authors":"Lvchang Zhu, Xinxin Zeng, Yi Shi, Yuhang Wu, Xiaoshan Zhang, Shanshan Xu, Xuben Yu, Lisu Huang","doi":"10.1093/infdis/jiaf169","DOIUrl":"https://doi.org/10.1093/infdis/jiaf169","url":null,"abstract":"Background Linezolid shows therapeutic potential for pediatric gram-positive bacterial central nervous system infections (CNSIs). However, its efficacy, safety profile, and cerebrospinal fluid (CSF) pharmacokinetics require detailed evaluation. Methods This prospective two-center observational study enrolled children with confirmed or suspected gram-positive CNSIs. Clinical outcomes and adverse events were compared between linezolid-treated patients and a matched vancomycin cohort. Population pharmacokinetic (PopPK) modeling with nonlinear mixed-effects analysis quantified linezolid exposure in plasma and CSF. Results Among 45 matched pediatric CNSIs patients per group, linezolid demonstrated a 91.1% clinical response rate and 68.9% cure rate (vancomycin cure rate: 68.9%). ‌However, non-inferiority to vancomycin was not established‌ for the primary endpoint, possibly influenced by intergroup baseline variability and extended treatment duration. Adverse events occurred more frequently with linezolid, including gastrointestinal (48.9% vs. 24.4%, p = 0.02) and hematologic effects (73.3% vs. 53.3%, p = 0.05). Plasma trough concentrations > 7 µg/mL were correlated with elevated risk of leukopenia and neutropenia (odds ratio [OR] 9.38, 95% confidence interval [CI] 1.21–72.6; and OR 40.2, 95% CI 2.15–748.50). However, no treatment discontinuations occurred due to adverse events. The PopPK model analyzed 135 linezolid concentrations (90 plasma/45 CSF), identifying body weight as the primary covariate influencing distribution. Plasma and CSF trough concentrations showed a strong correlation (r = 0.87, 95% CI 0.75–0.98). Conclusions Linezolid demonstrated favorable clinical efficacy and tolerability in pediatric CNSIs, with CSF concentrations ‌that correlated with plasma levels‌ and ‌exhibited predictable pharmacokinetics‌.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salmonella effector SseL induces PD-L1 up-regulation and T cell inactivation via β-catenin signalling axis","authors":"Umesh Chopra, Maria Kondooparambil Sabu, Raju S Rajmani, Ayushi Devendrasingh Chaudhary, Shashi Kumar Gupta, Dipshikha Chakravortty","doi":"10.1093/infdis/jiaf131","DOIUrl":"https://doi.org/10.1093/infdis/jiaf131","url":null,"abstract":"The upregulation of PD-L1 by various pathogens is a recognized strategy to evade the adaptive immune response. Salmonella infection also upregulates PD-L1 levels; however, the underlying mechanism remains unclear. Our study reveals that this upregulation is mediated by Salmonella pathogenicity island 2 (SPI-2) effectors, as PFA-fixed and STMΔssaV fail to alter PD-L1 levels. We have further investigated the role of the SPI-2 effector SseL (a deubiquitinase) in PD-L1 upregulation, and our study reveals SseL to be crucial for upregulating PD-L1 in vitro as well as in vivo murine models. STMΔsseL exhibits colonization defects in secondary infection sites such as the liver and spleen. Notably, STMΔsseL-infected mice show earlier mortality associated with heightened inflammation. Mechanistically, SseL stabilizes β-catenin, which translocates to the nucleus and leads to PD-L1 transcription, which is abrogated by the β-catenin/TCF inhibitor FH535. Collectively, our study elucidates the mechanism by which Salmonella mediates immune suppression through PD-L1 upregulation.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the impact of influenza epidemics in Hong Kong","authors":"Jessica Y Wong, Justin K Cheung, Anne M Presanis, Daniela De Angelis, A Danielle Iuliano, Peng Wu, Benjamin J Cowling","doi":"10.1093/infdis/jiaf140","DOIUrl":"https://doi.org/10.1093/infdis/jiaf140","url":null,"abstract":"Background Assessing the impact of influenza epidemics provides useful information to assess both population and healthcare system burden and can inform prevention and control measures for seasonal epidemics, such as vaccination and antivirals. Furthermore, it is an important component of pandemic preparedness. Methods We assessed and compared three influenza impact parameters: influenza-associated excess respiratory mortality, hospitalizations and ICU admissions, under the World Health Organization Pandemic Influenza Severity Assessment framework. We used a generalized additive model to estimate these parameters from 1998 through 2019 in Hong Kong based on historical mortality, hospitalization, ICU admission and influenza surveillance data. Intensity thresholds by influenza type were estimated using quantiles from the distribution of peak values of the parameters from 1998 through 2017 and were compared to the real-time estimates of excess parameters in 2018-2019. Influenza death and hospitalization data were used for validation. Findings There was good agreement between the different impact parameters after comparing the 2018-2019 data to the thresholds. The 2019 influenza A epidemic was characterized as having moderate impact overall and in all age groups, except 0-64 years for whom the excess ICU impact was high; whereas the 2018 influenza B epidemic was characterized as having very high impact overall and in all age groups. Interpretation The impact of influenza epidemics can vary from year to year. The PISA framework facilitates the impact assessment of seasonal influenza epidemics using different data sources and can be implemented in both real-time or at the end of seasons as policy makers and public health officials prepare for the next seasonal epidemic.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143661192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recovery of Antibody Immunity After a Resurgence of Respiratory Syncytial Virus Infections","authors":"Frederic Reicherz, Marina Viñeta Paramo, Jeffrey N Bone, Alexanne Lavoie, Sirui Li, Liam Golding, Agatha Jassem, Allison Watts, Bahaa Abu-Raya, Pascal M Lavoie","doi":"10.1093/infdis/jiaf101","DOIUrl":"https://doi.org/10.1093/infdis/jiaf101","url":null,"abstract":"Longitudinal measurements of respiratory syncytial virus (RSV) immunity over 4 winter seasons reveal that viral neutralization titers, RSV prefusion F protein (pre-F)–specific immunoglobulin M and immunoglobulin G (IgG) levels, and RSV antibody–dependent cellular phagocytosis function gradually returned to prepandemic levels in female healthcare and school workers of childbearing age after 2 winter seasons, following the resurgence of RSV cases in the Vancouver metropolitan region (British Columbia, Canada). In contrast, pre-F IgG avidity profiles remained unchanged. These findings support the notion that repeated viral infections are necessary to maintain high RSV antibody levels in the population.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children/Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America","authors":"Tarek El Hindi, Maria Theresa Alera, Lulu Bravo, Edson Duarte Moreira, Reynaldo Dietze, Ana Lucia Oliveira, Veerachai Watanaveeradej, Yuan Zhao, Ivo Sonderegger, Vianney Tricou, Nicolas Folschweiller, Shibadas Biswal","doi":"10.1093/infdis/jiaf145","DOIUrl":"https://doi.org/10.1093/infdis/jiaf145","url":null,"abstract":"Background TAK-003 has been shown to be well tolerated and effective against symptomatic dengue disease and hospitalization, irrespective of baseline serostatus. Most infections are asymptomatic/subclinical. This study assessed whether TAK-003 could protect against asymptomatic/subclinical infections by evaluating increased neutrlizing antibody titers (NAb) after natural infection. Methods DEN-301(NCT02747927) is a phase 3 trial among 4- to 16-year-old participants who received 2 doses of TAK-003/placebo 3 months apart. These exploratory analyses used NAb measured during the trial. As no well-accepted definition for asymptomatic infection exists, 3 algorithms were evaluated: (1) 4-fold increase in NAb, (2) 4-fold increase in NAb and a minimum titer of 40, and (3) 4-fold increase in NAb and a minimum titer of 4-fold lower-limit-of-quantification. Months 4-9, 9-15, and 15-27 after first vaccination were analyzed. Results NAb from 3765 participants were analyzed. From months 4-9, vaccine efficacy (VE) against asymptomatic infection was 51.1%(30.4 to 65.6), 36.1%(6.7–56.3), and 27.3%(−8.2 to 51.2) for algorithms 1, 2, and 3, respectively. VE in baseline seropositive participants per algorithms 1, 2, and 3 was 54.8%(28.8 to 71.3), 47.9%(16.8 to 67.4), and 44.3%(9.9 to 65.6), respectively, and in baseline seronegative participants was 44.4%(2.1 to 68.4), 4.6%(–85.1 to 50.8), and −29.3%(−172.1 to 38.6), respectively. VE against asymptomatic infection gradually decreased from months 4-9 to 9-15 and months 9-15 to 15-27. Conclusions The variability in VE algorithms indicates challenges in accurately assessing VE against asymptomatic infections. TAK-003 had a modest impact on asymptomatic dengue infections in the first months post-vaccination, mainly in baseline seropositive participants.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}